Revelation Biosciences, Inc. (REVB) financial statements (2022 and earlier)
Company profile
| Business Address |
5 WEST 21ST STREET NEW YORK, NY 10010 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 537 | |||
| Cash and cash equivalents | 12 | |||
| Short-term investments | 525 | |||
| Prepaid expense | 114 | |||
| Total current assets: | 651 | |||
| Noncurrent Assets | ||||
| Assets held-in-trust | 73,511 | |||
| Total noncurrent assets: | 73,511 | |||
| TOTAL ASSETS: | 74,162 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 34 | |||
| Accrued liabilities | 34 | |||
| Derivative instruments and hedges, liabilities | 3,400 | |||
| Total current liabilities: | 3,434 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 2,911 | |||
| Deferred revenue | 2,911 | |||
| Total noncurrent liabilities: | 2,911 | |||
| Total liabilities: | 6,345 | |||
| Temporary equity, carrying amount | 73,509 | |||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | (5,692) | |||
| Common stock | 2 | |||
| Accumulated deficit | (5,694) | |||
| Total stockholders' equity: | (5,692) | |||
| TOTAL LIABILITIES AND EQUITY: | 74,162 | |||
Income statement (P&L) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | ||
|---|---|---|---|
| Operating expenses | (145) | ||
| Operating loss: | (145) | ||
| Nonoperating expense (Other Nonoperating expense) | (1,485) | ||
| Net loss available to common stockholders, diluted: | (1,631) | ||
Comprehensive Income ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | ||
|---|---|---|---|
| Net loss: | (1,631) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,631) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.